Radioactive medicine for resistant neuroblastoma and pheochromocytoma
Part of Cancer clinical trials.
This trial uses a special radioactive medicine (131I-MIBG) to target and kill cancer cells in people with neuroblastoma or pheochromocytoma that has not responded to other treatments. It may help shrink tumors or slow the disease, and you'll receive a stem cell transplant afterward to help your body recover.
Summary written for real people, not researchers, by Clin2.
Who can take part
- You have neuroblastoma or pheochromocytoma that has come back or is not responding to standard treatment.
- Your tumor shows up on an MIBG scan (a special scan that finds these types of cancer).
- You have enough stored stem cells for a stem cell transplant after the treatment.
- Your organs (like bone marrow, kidneys, liver, heart, and lungs) are working well enough.
- You are not pregnant and have no active serious infections.
Quick eligibility check
Answer a few plain-language questions, based on this study's own requirements, to get a preliminary sense of fit.
Similar studies
Other trials that look related to this one.
This trial studies a radioactive medicine called iodine I-131 MIBG to shrink tumors that take up MIBG. It may help people whose neuroblastoma or malignant pheochromocytoma/paraganglioma has come back, progressed, or not responded to standard treatment.
This trial tests a radioactive drug called 211At-MABG for people with advanced neuroendocrine cancers that have stopped responding to other treatments. The drug targets cancer cells that show up on a special MIBG scan, delivering radiation directly to the tumor.
This trial tests a vaccine, combined with two other immune-boosting drugs (β-glucan and GM-CSF), to see if it can help keep neuroblastoma from coming back. It's for people who have already completed standard treatment and are in remission.
This trial gives a radioactive drug (131I-MIBG) that targets and kills certain nerve tumor cells. It is for people whose neuroblastoma or related tumors have not responded to standard treatments or have come back.
This trial tests a combination of a radioactive drug (MIBG) that targets neuroblastoma cells, with two other drugs that may help the radiation work better. It is for children and young adults with high-risk neuroblastoma that has come back or not gone away after standard treatment.
This early-phase trial tests a new drug called IR-101 for children with high-risk neuroblastoma that has come back or isn't responding to treatment. It aims to see if the drug is safe and can help shrink tumors that show up on a MIBG scan.
Hear when a new Neuroblastoma trial opens
We’ll email you when one opens — at most once a week, no account needed, unsubscribe anytime.